Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
Revenue Recognition [Line Items] | ||||
Total research and development revenue | $ 4,417 | $ 15,134 | $ 12,903 | $ 18,354 |
Millennium Pharmaceuticals, Inc. | ||||
Revenue Recognition [Line Items] | ||||
Total research and development revenue | 0 | 12,899 | 2,586 | 13,136 |
Millennium Pharmaceuticals, Inc. | Takeda Development and License Agreement | ||||
Revenue Recognition [Line Items] | ||||
Total research and development revenue | 0 | 12,899 | 0 | 13,114 |
Millennium Pharmaceuticals, Inc. | Takeda Multi-Target Agreement | ||||
Revenue Recognition [Line Items] | ||||
Total research and development revenue | $ 0 | $ 0 | $ 2,586 | $ 22 |
X | ||||||||||
- Definition Research and development revenues from collaboration agreements. No definition available.
|
X | ||||||||||
- Definition Revenue recognition. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|